Sugi Predict

Sugi Predict / Compounds / SCHEMBL2239581

SCHEMBL2239581

SCHEMBL2239581

CC1C(=O)Nc2cc(Br)ccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 2/20 0.45
▸ BMPR1B O00238 1/20 0.43
▸ BMPR1A P36894 1/20 0.43
▸ TGFBR1 P36897 1/20 0.43
▸ ACVRL1 P37023 1/20 0.43
▸ ACVR1 Q04771 1/20 0.43
▸ TP53 P04637 4/20 0.41
▸ MAPT P10636 3/20 0.41
▸ POLB P06746 1/20 0.41
▸ GABRA1 P14867 1/20 0.41
▸ GABRA5 P31644 1/20 0.41
▸ GABRA3 P34903 1/20 0.41
▸ GABRA2 P47869 1/20 0.41
▸ GABRB2 P47870 1/20 0.41
▸ CMA1 P23946 1/20 0.41
▸ AHR P35869 1/20 0.41
▸ NQO2 P16083 1/20 0.40
▸ LMNA P02545 2/20 0.38
▸ TGM2 P21980 1/20 0.38
▸ CES1 P23141 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31219834 1.00 PGR (0.45) PGRBMPR1BBMPR1ATGFBR1ACVRL1
SCHEMBL29891547 0.85 PGR (0.53) PGRTP53MAPTPOLBGABRA1
SCHEMBL3519770 0.85 PGR (0.53) PGRTP53MAPTPOLBGABRA1
SCHEMBL16668782 0.81 CMA1 (0.43) TP53MAPTPOLBGABRA1GABRA5
SCHEMBL24112743 0.79 PGR (0.46) PGRBMPR1BBMPR1ATGFBR1ACVRL1
SCHEMBL13091038 0.79 PGR (0.46) PGRBMPR1BBMPR1ATGFBR1ACVRL1
SCHEMBL24373457 0.79 GABRA1 (0.43) PGRTP53MAPTPOLBGABRA1
SCHEMBL24112918 0.78 PGR (0.60) PGRBMPR1BBMPR1ATGFBR1ACVRL1
SCHEMBL7268601 0.78 PGR (0.45) PGRBMPR1BBMPR1ATGFBR1ACVRL1
SCHEMBL24112740 0.78 PGR (0.45) PGRBMPR1BBMPR1ATGFBR1ACVRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4713096-A1 CDK INHIBITOR COMPOUNDS Aleksia Therapeutics, Inc. (US) 2026-03-25 — — EP disclosed
CN-119330982-A Azetidine compound and medical application thereof 中国科学院上海药物研究所 2025-01-21 — — CN disclosed
WO-2024238574-A1 CDK INHIBITOR COMPOUNDS ALEKSIA THERAPEUTICS, INC. (US) 2024-11-21 — — WO disclosed
WO-2024064316-A1 COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 INHIBITORS AND USES THEREOF REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2024-03-28 — — WO disclosed
CN-111433195-B Pyridone derivatives and their use as selective ALK-2 inhibitors 诺华股份有限公司 2023-04-25 — — CN disclosed
EP-3713927-B1 PYRIDINONE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS NOVARTIS AG (CH) 2021-12-15 — — EP disclosed
US-11160797-B2 Pyridinone derivatives and their use as selective ALK-2 inhibitors NOVARTIS AG (CH) 2021-11-02 — — US disclosed
US-11160797-B2 Pyridinone derivatives and their use as selective ALK-2 inhibitors NOVARTIS AG (CH) 2021-11-02 — — US disclosed
US-20200360357-A1 Pyridinone derivatives and their use as selective ALK-2 inhibitors NOVARTIS AG (CH) 2020-11-19 — — US disclosed
US-20200360357-A1 Pyridinone derivatives and their use as selective ALK-2 inhibitors NOVARTIS AG (CH) 2020-11-19 — — US disclosed
EP-2243779-A1 BICYCLIC HETEROCYCLIC DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2010-10-27 — — EP disclosed
WO-2009158011-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2009-12-30 — — WO disclosed
US-20030225127-A1 Heterocyclic sulfonamide derivatives BENDER DAVID MICHAEL (US) 2003-12-04 — — US disclosed
US-20030220369-A1 Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function FORMAN SCOTT LOUIS (US) 2003-11-27 — — US disclosed
EP-1313719-A2 HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USE FOR POTENTIATING GLUTAMATE RECEPTOR FUNCTION ELI LILLY AND COMPANY (US) 2003-05-28 — — EP disclosed
EP-1309577-A2 HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USE FOR POTENTIATING GLUTAMATE RECEPTOR FUNCTION ELI LILLY AND COMPANY (US) 2003-05-14 — — EP disclosed
WO-2002014275-A2 HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USE FOR POTENTIATING GLUTAMATE RECEPTOR FUNCTION ELI LILLY AND COMPANY (US) 2002-02-21 — — WO disclosed
WO-2002014294-A2 HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USE FOR POTENTIATING GLUTAMATE RECEPTOR FUNCTION ELI LILLY AND COMPANY (US) 2002-02-21 — — WO disclosed
US-5514690-A Aminocarbonyl (thiocarbonyl) and cyanoguanidine derivatives of quinoline and indoline E. R. SQUIBB & SONS, INC. (US) 1996-05-07 — — US disclosed
EP-0610553-A1 Aminocarbonyl (thiocarbonyl) and cyanoguanidine derivatives of quinoline and indoline E.R. SQUIBB & SONS, INC. (US) 1994-08-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200360357-A1 Pyridinone derivatives and their use as selective ALK-2 inhibitors ALK, ACVR2B, ACVR1B PGR 2882/4885BMPR1B 637/4885BMPR1A 1313/4885
US-11160797-B2 Pyridinone derivatives and their use as selective ALK-2 inhibitors ALK, ACVR2B, ACVR1B PGR 2882/4885BMPR1B 637/4885BMPR1A 1313/4885
US-20030225127-A1 Heterocyclic sulfonamide derivatives GRIN2A, GRIN2B, GRIN1 PGR 2713/4885BMPR1B 3205/4885BMPR1A 2413/4885
US-20030220369-A1 Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function GRIN2A, GRIN1, GRIN2B PGR 2248/4885BMPR1B 2976/4885BMPR1A 2087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.